UTHR
United Therapeutics Corporation
NASDAQ: UTHR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$569.88
+0.40% today
Updated 2026-06-05
Market cap
$23.17B
P/E ratio
20.21
P/S ratio
7.31x
EPS (TTM)
$27.02
Dividend yield
—
52W range
$272 – $609
Volume
0.5M
United Therapeutics Corporation (UTHR) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed UTHR price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$569.88
Today
Analyst consensus
$663.58
+16.44% · 12M
2030 Base
$894.77
+57.01% future
NPV today
$632.91
@ 8% WACC
14 analysts:
11 Buy3 Hold0 Sell
Management guidance
CEO Martine Rothblatt provided guidance expecting revenue to reach $4.0 billion by end of 2027 (vs. $3.18B in 2025), implying ~25.8% CAGR over 2 years. This guidance is anchored by two major new drug launches: Tyvaso DPI for IPF (idiopathic pulmonary fibrosis) and ralinepag for PAH (pulmonary arterial hypertension), both with Phase 3 success and superior clinical outcomes vs. competitors. Management also disclosed RALDPI (inhaled ralinepag formulation) targeting multiple indications (IPF, PAH, ILD, PPF) as their 'biggest product' opportunity, suggesting multi-indication expansion beyond core pulmonary hypertension franchise.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
UTHR · United Therapeutics Corporation · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$532.20
NPV today: $376.45
Base case (2030)
$894.77
NPV today: $632.91
Bull case (2030)
$1,619.90
NPV today: $1,145.82
WallStSmart.com
UTHR financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.5B | $4.4B | $5.4B | $6.6B | $7.8B |
| Revenue growth | 10.6% | 10.8% | 24.4% | 23.8% | 21.4% | 19.3% |
| Net margin | — | 38.2% | 38.1% | 38.5% | 38.1% | 37.8% |
| EPS | $27.90 | $31.50 | $39.00 | $48.50 | $58.00 | $68.50 |
| Diluted shares | — | 43M | 43M | 43M | 43M | 43M |
| Net debt | — | $-3.35B | $-4.07B | $-4.97B | $-6.05B | $-7.35B |
| P/S multiple | — | 4.0x | 4.0x | 4.0x | 4.0x | 4.0x |
| Implied price (base) | — | $408.55 | $504.11 | $619.64 | $749.79 | $894.77 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $7.8B | $7.8B | $7.8B |
| P/S multiple | 2.0x | 4.0x | 8.0x |
| Diluted shares | 43M | 43M | 43M |
| Net debt | $-7.35B | $-7.35B | $-7.35B |
| Implied P/E † | 8x | 13x | 24x |
| 2030 Price | $532.20 | $894.77 | $1,619.90 |
| NPV @ 8% | $376.45 | $632.91 | $1,145.82 |
† Implied P/E: Multiples remain elevated across all three scenarios because UTHR is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $894.77 base case
UTHR catalysts and risks
Growth catalysts
+ TETON-1 Phase 3 (Tyvaso DPI for IPF) published in NEJM May 2026 with positive primary endpoint; FDA priority review expected; IPF is large untapped market (~$8B+ peak sales potential)
+ Ralinepag (PAH) Phase 3 ADVANCE OUTCOMES showed 55% reduction in clinical worsening risk; regulatory submissions underway for PAH approval; PAH patient base expanding with superior efficacy profile vs. approved agents
+ RALDPI (inhaled ralinepag) development across 4 indications (IPF, PAH, ILD, PPF) with multiple regulatory pathways; management indicated this as company's 'biggest product opportunity'
+ UHeart xenotransplantation FDA clearance for first-in-human trial (May 2026); long-term transformational potential beyond current rare pulmonary franchise
+ Varda Space Industries partnership for microgravity drug development; early-stage but positions UTHR at forefront of novel manufacturing and drug formulation enhancement
+ Strong balance sheet ($2.15B net cash Q1 2026) enabling aggressive pipeline investment and potential M&A or partnerships in complementary areas
Key risks
- Regulatory execution risk: Tyvaso DPI and ralinepag approvals not guaranteed despite Phase 3 success; FDA could require additional data or impose restrictive label
- Competition: Established PAH/IPF competitors (Actelion/Janssen, Gilead, Roche) have large installed bases and payer relationships; new entrants face formulary/reimbursement barriers
- Commercial execution risk: launch of two major new drugs simultaneously (2026-2027) requires significant sales force expansion and healthcare provider education; execution delays could compress peak revenue trajectory
- Insider selling: CEO, CFO, and EVP executing significant share sales ($15M+ in aggregate May 2026) despite stock near 52-week highs; potential signal of valuation concerns or reduced insider confidence
- Patent/exclusivity cliff risk: core Tyvaso and Remodulin franchises face biosimilar/generic competition starting mid-2030s if no life-cycle management (combination therapies, new formulations) succeed
- IPF/PAH market adoption uncertainty: ralinepag and Tyvaso DPI efficacy is superior in trials, but real-world adoption depends on payer coverage, physician adoption, and patient adherence; slow ramp could delay peak revenue
Methodology · United Therapeutics Corporation 2030 stock forecast model
United Therapeutics Corporation 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for UTHR by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-7.35B by 2030) |
| 3. Time value | NPV calculated using 8% WACC (CAPM: beta 0.595) |
| 4. Multiple framework | P/S compresses with scale: bear 2.0x / base 4.0x / bull 8.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
UTHR price target FAQ
What is the UTHR price target for 2030?
WallStSmart's United Therapeutics Corporation 2030 base case is $894.77 per share, with a bull case of $1,619.90 and bear case of $532.20. The NPV of the base case discounted to today at 8% WACC is $632.91.
How is the United Therapeutics Corporation 2030 stock forecast calculated?
The UTHR 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the UTHR price target account for dilution?
United Therapeutics Corporation is projected to grow diluted share count from 42M to 43M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on UTHR stock?
14 analysts cover UTHR with an average 12-month price target of $663.58. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.